The stock of Editas Medicine Inc (EDIT) has seen a -3.06% decrease in the past week, with a -9.69% drop in the past month, and a -37.60% decrease in the past quarter. The volatility ratio for the week is 5.08%, and the volatility levels for the past 30 days are at 5.61% for EDIT. The simple moving average for the last 20 days is -10.88% for EDIT stock, with a simple moving average of -48.16% for the last 200 days.
Is It Worth Investing in Editas Medicine Inc (NASDAQ: EDIT) Right Now?
The stock has a 36-month beta value of 1.99. Opinions on the stock are mixed, with 4 analysts rating it as a “buy,” 0 as “overweight,” 4 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for EDIT is 81.70M, and at present, short sellers hold a 23.21% of that float. On October 09, 2024, the average trading volume of EDIT was 1.79M shares.
EDIT) stock’s latest price update
Editas Medicine Inc (NASDAQ: EDIT) has seen a decline in its stock price by -1.25 in relation to its previous close of 3.21. However, the company has experienced a -3.06% decline in its stock price over the last five trading sessions. gurufocus.com reported 2024-10-07 that Shares of Editas Medicine, Inc. (EDIT, Financial), a biopharmaceutical company, experienced a notable drop of 5.18%. The stock is currently priced at $3.21 per share, with a trading volume of 976,255 shares and a turnover rate of 1.18%.
Analysts’ Opinion of EDIT
Many brokerage firms have already submitted their reports for EDIT stocks, with BofA Securities repeating the rating for EDIT by listing it as a “Buy.” The predicted price for EDIT in the upcoming period, according to BofA Securities is $15 based on the research report published on August 08, 2024 of the current year 2024.
Morgan Stanley, on the other hand, stated in their research note that they expect to see EDIT reach a price target of $7. The rating they have provided for EDIT stocks is “Equal-Weight” according to the report published on May 09th, 2024.
Citigroup gave a rating of “Buy” to EDIT, setting the target price at $11 in the report published on October 24th of the previous year.
EDIT Trading at -18.08% from the 50-Day Moving Average
After a stumble in the market that brought EDIT to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -72.88% of loss for the given period.
Volatility was left at 5.61%, however, over the last 30 days, the volatility rate increased by 5.08%, as shares sank -15.92% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -41.30% lower at present.
During the last 5 trading sessions, EDIT fell by -3.06%, which changed the moving average for the period of 200-days by -68.95% in comparison to the 20-day moving average, which settled at $3.56. In addition, Editas Medicine Inc saw -68.71% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at EDIT starting from Mei Baisong, who sale 518 shares at the price of $3.42 back on Sep 04 ’24. After this action, Mei Baisong now owns 133,895 shares of Editas Medicine Inc, valued at $1,774 using the latest closing price.
O’Neill Gilmore Neil, the CEO of Editas Medicine Inc, sale 1,555 shares at $3.42 during a trade that took place back on Sep 04 ’24, which means that O’Neill Gilmore Neil is holding 313,724 shares at $5,325 based on the most recent closing price.
Stock Fundamentals for EDIT
Current profitability levels for the company are sitting at:
- -3.1 for the present operating margin
- 0.91 for the gross margin
The net margin for Editas Medicine Inc stands at -2.89. The total capital return value is set at -0.67. Equity return is now at value -61.23, with -41.75 for asset returns.
Based on Editas Medicine Inc (EDIT), the company’s capital structure generated 0.14 points at debt to capital in total, while cash flow to debt ratio is standing at -4.25. The debt to equity ratio resting at 0.17. The interest coverage ratio of the stock is -59.92.
Currently, EBITDA for the company is -163.12 million with net debt to EBITDA at 0.13. When we switch over and look at the enterprise to sales, we see a ratio of 3.52. The receivables turnover for the company is 274.73for trailing twelve months and the total asset turnover is 0.17. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.85.
Conclusion
To sum up, Editas Medicine Inc (EDIT) has seen a bad performance recently. Analysts have differing views on the stock, with some seeing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
